These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29019795)

  • 1. DIFFERENCE IN TREATMENT OUTCOMES ACCORDING TO OPTICAL COHERENCE TOMOGRAPHY-BASED STAGES IN TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION).
    Kim JH; Chang YS; Kim JW; Kim CG; Lee DW; Cho SY
    Retina; 2018 Dec; 38(12):2356-2362. PubMed ID: 29019795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH
    Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis.
    Kim JH; Kim JW; Kim CG; Lee DW
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1661-1669. PubMed ID: 31144056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
    Lee EK; Yu HG
    Korean J Ophthalmol; 2019 Jun; 33(3):228-237. PubMed ID: 31179654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
    Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
    Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION.
    Hata M; Yamashiro K; Oishi A; Ooto S; Tamura H; Miyata M; Ueda-Arakawa N; Kuroda Y; Takahashi A; Tsujikawa A; Yoshimura N
    Retina; 2017 Nov; 37(11):2069-2077. PubMed ID: 28085772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
    Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
    Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
    Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
    Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RECURRENCE IN PATIENTS WITH TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION) AFTER INTRAVITREAL RANIBIZUMAB.
    Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
    Retina; 2017 Aug; 37(8):1508-1515. PubMed ID: 27787444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
    Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
    Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.